A Medicare card superimposed over a maze
Each fall, Medicare's annual open enrollment period — from Oct. 15 through Dec. 7 — gives beneficiaries a chance to evaluate and update their health and drug coverage for the coming year.
While attention tends to focus on plan premiums and provider networks, 2026 introduces several program changes that could influence how enrollees budget, access benefits and choose coverage.
These changes reflect continued implementation of provisions from the Inflation Reduction Act and final guidance from the Centers for Medicare & Medicaid Services.
They may not dominate headlines, but they carry implications that advisors and beneficiaries alike should consider when reviewing plan options.
The Question:
What Medicare changes are scheduled for 2026, and how might they affect beneficiaries during open enrollment?
The Answer:
The following policy changes and cost adjustments will go into effect in 2026 and may impact Medicare plan selection, prescription budgeting and benefit utilization.
Prescription drug spending will be capped.
For the first time, Medicare Part D coverage will include an annual out-of-pocket maximum of $2,100.
Once this threshold is reached, beneficiaries will owe nothing more for covered prescriptions for the rest of the calendar year.
This cap modifies the catastrophic phase so that once a beneficiary reaches the new out-of-pocket threshold, they no longer pay coinsurance or copayments for covered Part D drugs for the rest of the year.
For those taking costly or multiple maintenance medications, this change offers meaningful financial protection and a more predictable end-of-year budget.
A monthly drug payment plan offers budgeting flexibility.
The Medicare Prescription Payment Plan, introduced in 2025, remains active in 2026.
It enables beneficiaries to spread out-of-pocket prescription drug costs evenly over the calendar year, rather than paying in full at the time of pickup.
For example, a beneficiary prescribed a $600 drug in January may choose to pay that cost in equal monthly installments, easing cash flow and avoiding lump-sum expenses early in the year.
Insulin costs remain capped.
The monthly $35 cap on insulin, originally enacted under the Inflation Reduction Act, continues in 2026.
This applies to insulin products covered by Medicare Part D and Medicare Advantage with drug coverage, and no deductible applies.
For insulin users, this cap provides ongoing cost certainty, regardless of when prescriptions are filled or whether the plan's deductible has been met.
Vaccines continue at no cost.
Vaccines recommended by the Advisory Committee on Immunization Practices will remain free for Medicare beneficiaries under Part D.
Insurers must continue to waive both deductibles and cost-sharing for ACIP-approved adult vaccines.
This applies specifically to ACIP-recommended vaccines covered under Part D.
Some vaccines, such as flu, pneumococcal, hepatitis B for high-risk groups, and COVID-19, are covered under Part B instead.
This provision supports access to preventive care.
For example, a beneficiary planning international travel in 2026 can receive required vaccines at no cost if administered by an in-network provider.
The standard Part D deductible will rise.
The maximum allowable deductible for Part D drug plans will increase to $615 in 2026, up from $590 in 2025.
For beneficiaries whose drug expenses exceed their deductible early in the year, this $25 increase may result in higher initial out-of-pocket spending before coinsurance begins.
Reviewing the annual notice of change remains critical.
The ANOC details adjustments in coverage, costs and networks for the upcoming year.
Even beneficiaries who are satisfied with their current plan may discover that a covered drug has been moved to a different tier or that a local pharmacy is no longer in-network.
Reviewing the ANOC ensures informed plan comparisons during open enrollment.
For the 2026 plan year, Medicare continues its transition toward more predictable drug costs and broader access to preventive services.
While these changes may not affect every enrollee equally, they offer additional tools for managing care and cost — particularly for those with ongoing medication needs or tight monthly budgets.
Advisors are encouraged to help clients interpret these changes within the context of their personal health priorities.
Whether it's reviewing cost-sharing thresholds, choosing installment billing for prescriptions, or understanding the implications of deductible increases, the decisions made during this open enrollment window may shape a beneficiary's health care experience throughout the year.
Tricia Blazier, J.D., is director of Healthcare Insurance Services at Allsup.
Credit: CMS
© Touchpoint Markets, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.